Pentoxifylline for the prevention of contrast-induced nephropathy (CIN): systematic review and meta-analysis of randomised controlled trials

This review of 7 RCTs (n=1484) found no significant reduction in CIN rate observed in patients treated with pentoxifylline (PTX) vs control groups. Overall rates of CIN were 8.8% and 10.4% in PTX and control groups, respectively (OR 0.81, 95% CI 0.57 to 1.13, I2=0, p=0.21).

BMJ Open